Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 02, 2025 10:47 ET | Source: Bragar Eagel & Squire

TEMPUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Tempus AI, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Tempus (TEM) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities...
July 28, 2025 19:13 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis and Tempus and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vestis (VSTS) or Tempus (TEM) To Contact Him Directly To Discuss Their Options If you...
July 24, 2025 18:51 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis, Reckitt, and Tempus and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vestis (VSTS), Reckitt (RBGLY), or Tempus (TEM) To Contact Him Directly To Discuss Their...
July 20, 2025 11:07 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis, Reckitt, and Tempus and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vestis (VSTS), Reckitt (RBGLY), or Tempus (TEM) To Contact Him Directly To Discuss Their...
July 12, 2025 15:12 ET | Source: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis, PepGen, Reckitt, and Tempus and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vestis (VSTS), PepGen (PEPG), Reckitt (RBGLY), or Tempus (TEM) To Contact Him Directly To...
February 21, 2025 08:30 ET | Source: Stemline Therapeutics, Inc.

Tempus and Stemline Therapeutics, Inc., A Subsidiary of the Menarini Group, Announce Collaboration to Implement Tempus Next, an AI-Enabled Care Pathway Intelligence Platform to Support Patients with Metastatic Breast Cancer

Up to 50% of patients with ER+/HER2- mBC could develop ESR1 mutations as a result of prior exposure to endocrine therapy in the metastatic setting. Testing to identify these mutations can help...
October 21, 2024 07:00 ET | Source: Avacta Group

Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology

Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology LONDON – Oct. 21, 2024 – Avacta...